Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications
Status:
Withdrawn
Trial end date:
2020-11-02
Target enrollment:
Participant gender:
Summary
The purpose of this 9-day study is to determine if:
1. Pantoprazole modifies the steady-state plasma concentrations of orally administered
psychotropic medications including valproic acid, lithium, and second-generation
antipsychotics (i.e., aripiprazole, asenapine, clozapine, lurasidone, olanzapine,
paliperidone, quetiapine, risperidone, ziprasidone)
2. Serum gastrin levels change within a week of starting or stopping pantoprazole